Physician profile
Jeffrey E Mathews
NPI 1285635656
$1,715.27
in general payments reported to CMS, 2019-2025
13 companies · $380 in 2025
The $380 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $278 · 2023: $496 · 2024: $284 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,075.50 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $361.81 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $340.86 | 2024-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $243.96 | 2022-2023 | |
| Janssen Biotech, INC. | $227.69 | 2021-2025 | Tremfya |
| Braintree Laboratories, INC. | $137.21 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.09 | 2023 | Trulance |
| E.R. Squibb & Sons, L.L.C. | $81.11 | 2022 | |
| Daiichi Sankyo INC. | $69.72 | 2022-2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $56.31 | 2024-2025 | Entyvio, Eohilia |
| Ironwood Pharmaceuticals, INC | $16.67 | 2023 | Linzess |
| Pfizer INC. | $16.17 | 2023 | |
| Celgene Corporation | $14.99 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.68 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.